株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

中国の医薬品用ガラス包装産業の分析

China Pharmaceutical Glass Packaging Industry Report, 2014-2017

発行 ResearchInChina 商品コード 299557
出版日 ページ情報 英文 60 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
中国の医薬品用ガラス包装産業の分析 China Pharmaceutical Glass Packaging Industry Report, 2014-2017
出版日: 2015年06月02日 ページ情報: 英文 60 Pages
概要

2013年現在、中国の医薬品用ガラス瓶市場の規模は800億個(25〜30万トン相当)となっています。プラスチック・アルミホイルや他の新素材による代替、および医療改革に伴う包装素材購入価格の低迷を受けて、中国の医薬品用ガラス包装産業は低迷状態が続いています。一方で、参入障壁が低いことから、低級・中級品市場は深刻な設備過剰の状態に陥っている一方、高級品市場は輸入品への依存が続いています。現在、先進国では高品質・耐水性・天然性の硼珪酸ガラスが好まれていますが、中国ではいまだに低品質の硼珪酸ガラスやナトリウム・カルシウムガラス、そして「準天然性」硼珪酸ガラス(化学的安定性が自然の要件を満たさず、重金属の含有量が不明で、寸法が正確でないもの)が主に供給されています。注射用のプレフィルドシリンジについては、中国は主に外資系企業からの輸入に依存しています。

当レポートでは、中国における医薬品パッケージ用ガラス産業について分析し、全体的な市場構造や生産量・消費量の動向見通し、部門別の詳細動向、対外貿易の状況、主な国内系・外資系企業のプロファイルと業績などを調査しており、その結果をお届けします。

第1章 医薬品用ガラス包装素材の概要

  • 定義と分類
  • 関連産業

第2章 中国の医薬品用ガラス産業の発展

  • 現状
  • 市場規模
  • 競争パターン
  • 輸出入
  • プレフィルド注射システム
    • 定義と分類
    • 現状
    • 競争パターン
    • 価格分析
  • 川下からの需要
    • ワクチン
    • 血液製剤
    • インスリン
    • ヘパリン
    • インターフェロン
    • rhG-CSF(遺伝子組換えヒトG-CSF製剤)
  • 発展傾向

第3章 主要な医薬品用ガラス企業

  • Becton, Dickinson and Company
    • プロファイル
    • 経営状況
    • 収益構造
    • 医薬品用包装素材事業
    • 中国での事業展開
  • Gerresheimer AG
  • SCHOTT AG
  • ニプロ
  • Shandong Pharmaceutical Glass
  • Shandong Weigao Group Medical Polymer Co., Ltd.
  • Cangzhou Four Stars Glass
  • Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
  • Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
  • Linuo Glassworks Group

第4章 サマリーと予測

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: ZYM065

In recent years, advances in new healthcare reform have boosted market demand from China pharmaceuticals industryand driven growth in the demand from pharmaceutical packaging industry. In 2014, the Chinese pharmaceutical packaging market reached RMB72 billion, up 10.6% from a year earlier.

As a traditional form of pharmaceutical packaging bottle, pharmaceutical glass bottle took up a large proportion of the Chinese pharmaceutical packaging market in initial development stage of the packaging market. However, affected by negative factors like the substitution of new packaging materials (plastics and aluminum foil) and continuous decline in purchase prices of packaging materials quoted by pharmaceutical companies due to reform in medical system, China pharmaceutical glass packaging industry has developed sluggishly, with its market share standing at estimated 45% or so for the time being.

Due to low barrier to entry, China's pharmaceutical glass industry has been large but not strong as a whole, with low and medium-end products struggling with huge overcapacity and high-end products relying on imports. At present, developed countries around the world all use level I waterproof neutral borosilicate glass, while China still mostly adopts low borosilicate glass, soda-lime glass and almost domestically unique "semi-neutral borosilicate pharmaceutical glass" (its chemical stability cannot meet neutral requirements; the heavy metal content in glass is not defined clearly; dimensions are not accurate).

The production of neutral borosilicate glass faces dual barriers of raw materials and tube-making technology, which have been still controlled by foreign companies so far, resulting in persistently high production costs and limited applications. In 2012, German Schott AG, a world well-known pharmaceutical glass company, together with Zhejiang Xinkang Pharmaceutical Glass Co., Ltd., announced to establish a joint venture that would engage in pharmaceutical packaging, an important sign marking localization of pharmaceutical glass. But, even for the joint venture, it has to buy glass tube produced by Schott abroad.

However, the defect of low borosilicate glass easily flaking causes safety risks to health of users, so it is imperative to promote neutral borosilicate glass. Market demand for neutral borosilicate glass pharmaceutical containers has been growing by more than 20% over the past two years. More and more pharmaceutical players started to use neutral borosilicate glass, especially for high value-added products. For example, Buchang Pharma employs neutral borosilicate glass packaging materials for all its Danhong Injections, and some innovative R&D-oriented pharmaceutical companies like Jiangsu Hengrui Medicine Co., Ltd. also adopt neutral borosilicate glass.

With years of development and competition, the Chinese pharmaceutical glass business market still finds a relatively low level of concentration, but competitively leading companies have emerged in some market segments, especially in prefilled syringe market.

There are only five companies that have obtained assemblages for prefilled syringes in China, i.e., foreign-funded BD and Gerresheimer and domestic Shandong Weigao Group Medical Polymer, Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd. and Shandong Pharmaceutical Glass Co., Ltd.

By virtue of first-mover advantage and developed marketing network, Shandong Weigao Group Medical Polymer sold about 85.85 million prefilled syringes in 2014, accounting for more than 50% of the market in China, followed by foreign brands such as BD and Gerresheimer with market share of about 25%, and Zibo Minkang Pharmaceutical and Shandong Pharmaceutical Glass (the remaining). In addition, Shandong Weigao Group Medical Polymer still plans to implement the 50-million prefilled syringes project, which is expected to further raise the company's share in prefilled system market.

China Pharmaceutical Glass Packaging Industry Report, 2014-2017 highlights the followings:

  • Status quo, market size, import & export, downstream demand and development forecast of China pharmaceutical glass industry;
  • Status quo, competitive landscape and price of China prefilled syringe industry;
  • Operation, pharmaceutical glass business and development prospects of 4 global and 6 domestic pharmaceutical glass packaging companies.

Table of Contents

1 Overview of Pharmaceutical Glass Packaging Materials

  • 1.1 Definition and Classification
  • 1.2 Industry Chain

2 Development of China Pharmaceutical Glass Industry

  • 2.1 Status Quo
  • 2.2 Market Size
  • 2.3 Competitive Landscape
  • 2.4 Import & Export
  • 2.5 Prefilled Injection System
    • 2.5.1 Definition and Classification
    • 2.5.2 Status Quo
    • 2.5.3 Competitive Landscape
    • 2.5.4 Price
  • 2.6 Downstream Demand
    • 2.6.1 Vaccine
    • 2.6.2 Blood Product
    • 2.6.3 Insulin
    • 2.6.4 Heparin
    • 2.6.5 Interferon
    • 2.6.6 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
  • 2.7 Development Trend

3 Major Pharmaceutical Glass Companies

  • 3.1 Becton, Dickinson and Company
    • 3.1.1 Profile
    • 3.1.2 Operation
    • 3.1.3 Revenue Structure
    • 3.1.4 Pharmaceutical Packaging Materials Business
    • 3.1.5 Business in China
  • 3.2 Gerresheimer AG
    • 3.2.1 Profile
    • 3.2.2 Operation
    • 3.2.3 Revenue Structure
    • 3.2.4 Business in China
  • 3.3 SCHOTT AG
    • 3.3.1 Profile
    • 3.3.2 Operation
    • 3.3.3 Pharmaceutical Packaging Materials Business
    • 3.3.4 Business in China
  • 3.4 Nipro Medical Corporation
    • 3.4.1 Profile
    • 3.4.2 Operation
    • 3.4.3 Revenue Structure
    • 3.4.4 Pharmaceutical Packaging Materials Business
    • 3.4.5 Business in China
    • 3.4.5.1 ChengDuPingYuanNipro Pharmaceutical Packaging Co., Ltd.
    • 3.4.5.2 Jilin NiproJiaheng Pharmaceutical Packaging Co., Ltd.
    • 3.4.5.3 Anyang NiproChangda Pharmaceutical Packaging Co., Ltd.
  • 3.5 Shandong Pharmaceutical Glass Co., Ltd
    • 3.5.1 Profile
    • 3.5.2 Operation
    • 3.5.3 Revenue Structure
    • 3.5.4 Gross Margin
    • 3.5.5 Development Prospects and Forecast
  • 3.6 Shandong Weigao Group Medical Polymer Co., Ltd.
    • 3.6.1 Profile
    • 3.6.2 Operation
    • 3.6.3 Revenue Structure
    • 3.6.4 Gross Margin
    • 3.6.5 R&D and Investment
    • 3.6.6 Major Customers
    • 3.6.7 Pharmaceutical Packaging Materials Business
    • 3.6.8 Development Prospects and Forecast
  • 3.7 Cangzhou Four Stars Glass Co., Ltd.
  • 3.8 Shandong Zibo Minkang Pharmaceutical Packing Co., Ltd.
  • 3.9 Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
  • 3.10 Linuo Glassworks Group

4 Summary and Forecast

Selected Charts

  • Classification and Applications of Pharmaceutical Glass
  • New Pharmaceutical Glass Packaging and Application
  • Diagram of Pharmaceutical Glass Packaging Industry Chain
  • Market Size of China Pharmaceutical Packaging Industry, 2010-2014
  • Output of Human Powder Injection (Including Freeze-dried) and Injection in China, 2010-2014
  • Output of Large Volume Parenterals (LVPs) in China, 2010-2014
  • Revenue and YoY Growth of Veterinary Drug Industry in China, 2007-2014
  • Import and Export Volume of Glass Ampoule in China, 2011-2014
  • Import and Export Value of Glass Ampoule in China, 2011-2014
  • Average Import and Export Price of Glass Ampoule in China, 2011-2014
  • Materials for Prefilled Syringes
  • Classification of Prefilled Syringe and Structural Diagram
  • Prefilled Syringe Suppliers in China and Their Products
  • Major Prefilled Syringe Manufacturers and Their Capacity, 2014
  • Price of Some Prefilled Drugs in China, 2010-2014
  • Market Size of Pharmaceuticals Industry in China, 2011-2015
  • Lot Release Volume of EPI an Extra EPI in China, 2007-2014
  • Lot Release Volume of Blood Products in China by Product, 2008-2014
  • Market Size of Insulin Drugs in China, 2007-2014
  • Theoretical Capacity of Heparin Sodium API in China, 2008-2014
  • Market Size and YoY Growth of Heparin Preparations in China, 2007-2014
  • Market Size and Sales Volume of Recombinant Interferon in China, 2013-2019E
  • Market Size and Sales Volume of rhG-CSF in China, 2013-2019E
  • List of Primary Businesses of BD
  • Revenue and Operating Income of BD, FY2010-FY2014
  • Revenue Structure of BD by Business, FY2013-FY2014
  • Revenue Structure of BD by Region, FY2013-FY2014
  • BD's Revenue Breakdown from Medical Business by Product, FY2011-FY2014
  • Revenue Structure of Gerresheimer by Consumption Market, 2014
  • Revenue and Operating Income of Gerresheimer, 2009-2014
  • Revenue Breakdown of Gerresheimer by Business, 2009-2014
  • Revenue Structure of Gerresheimer by Region, 2014
  • Revenue and Profit of SCHOTT, FY2013-FY2014
  • Revenue Breakdown of SCHOTT by Region, FY2013-FY2014
  • SCHOTT's Subsidiaries in China
  • Revenue and Net Income of Nipro, FY2010-FY2014
  • Revenue Structure of Nipro by Business, FY2013-FY2014
  • Revenue Structure of Nipro by Region, FY2014
  • Nipro's Revenue from Glass Products Business and % of Total Revenue, FY2012-FY2014
  • Nipro's Key Subsidiaries in China and Their Businesses
  • List of Main Products of Shandong Pharmaceutical Glass
  • Revenue and Net Income of Shandong Pharmaceutical Glass, 2008-2015
  • Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Product, 2008-2014
  • Operating Revenue Breakdown of Shandong Pharmaceutical Glass by Region, 2008-2014
  • Gross Margin of Shandong Pharmaceutical Glass by Product, 2008-2014
  • Revenue and Gross Margin of Shandong Pharmaceutical Glass, 2014-2017E
  • Variety of Products and Main Products of Shandong Weigao Group Medical Polymer
  • Revenue and Net Income of Shandong Weigao Group Medical Polymer, 2009-2014
  • Revenue Breakdown of Shandong Weigao Group Medical Polymer, 2013-2014
  • Main High Value-added Conventional Medical Consumables of Shandong Weigao Group Medical Polymer
  • Revenue Breakdown of Shandong Weigao Group Medical Polymer by Region, 2008-2014
  • Prefilled Syringe Output and Sales of Shandong Weigao Group Medical Polymer, 2011-2014
  • Market Size of Pharmaceutical Packaging Industry in China, 2014-2017E
Back to Top